<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693781</url>
  </required_header>
  <id_info>
    <org_study_id>Co-ALS</org_study_id>
    <nct_id>NCT03693781</nct_id>
  </id_info>
  <brief_title>Colchicine for Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>Co-ALS</acronym>
  <official_title>Colchicine for Amyotrophic Lateral Sclerosis: a Phase II, Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria di Modena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Auxologico Italiano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS National Neurological Institute &quot;C. Mondino&quot; Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Di Ricerche Farmacologiche Mario Negri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria di Modena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the effects of two different Colchicine doses (0.01mg/kg/day or 0.005
      mg/kg/day) compared to placebo in Amyotrophic Lateral Sclerosis (ALS) patients. Disease
      progression as defined by changes in ALSFRS-r is the primary outcome measure. Other measures
      of clinical progression and survival, together with safety and tolerability of Colchicine in
      ALS patients will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent evidence supports the disruption of the ubiquitin-proteasome-system and autophagy as
      central events in ALS. ALS is characterized by the presence of misfolded proteins prone to
      oligomerize into aggregates, which exert a toxic effect by affecting several intracellular
      functions. Heat shock protein B8 (HSPB8) recognizes and promotes the autophagy-mediated
      removal of misfolded mutant SOD1 and TDP-43 fragments from ALS motor neurons (MNs). Moreover,
      HSPB8-BAG3-HSP70 maintains the so called &quot;granulostasis&quot;, a surveillance mechanism that
      avoids the conversion of dynamic stress granules (SGs) into aggregation-prone assemblies,
      which are a hallmark of ALS.

      Colchicine enhances the expression of HSPB8 and of several autophagy players while blocking
      TDP-43 accumulation in neurons. Moreover, given the cross-talk between infalmmation and
      autophagy, the well-known antinflammatory action of Cochicine may contribute to cell
      homeostasis.

      Based on these premises, this is a phase II randomized, double-blind, placebo-controlled,
      multicenter (9 MND Centres in Italy: 2 centres in Milan, Pavia, Turin, Modena, Padua, Rome,
      Naples, Bari), clinical trial to test efficacy of Colchicine in ALS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three arms of 18 patients each; in two arms two colchicine dosages will be tested compared to placebo in the control arm. The three arms will undergo treatment vs placebo in parallel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>placebo will be unrecognizable from active treatment (both in tablets)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in ALS disease progression as measured by ALS Functional rating Scale Revised (ALSFRS-R)</measure>
    <time_frame>comparison between baseline and treatment end (week 30)</time_frame>
    <description>ALSFRS-R is a scale that measures disability in ALS; the scores range from 0 (maximum disability, the worst score) to 48 (no disability, the best score). We will measure total score changes from baseline to week 30 in treatment and placebo arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (safety and tolerability)</measure>
    <time_frame>week 30 and 54</time_frame>
    <description>Number of serious adverse events (SAEs) and AEs in placebo and treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracheostomy-free survival rate</measure>
    <time_frame>Up to week 54</time_frame>
    <description>Overall survival from randomization to date of death or tracheostomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Forced Vital Capacity (FVC)</measure>
    <time_frame>Up to week 54</time_frame>
    <description>Changes in FVC score from baseline to week 8, 18, 30, 54 in treatment and placebo arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>at 8,18,30 and 54 week</time_frame>
    <description>Changes in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) from baseline to week 8, 18, 30 and week 54, in placebo and treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>enhancement of autophagy</measure>
    <time_frame>at week 30 and 54, compared to baseline</time_frame>
    <description>assessment of mRNA and protein levels of p62, LC3, TFEB, ATGs, HSPB8, BAG3, BAG1, HSP70, and HSF1, in patients' PBMCs, lymphoblasts and fibroblasts (transcriptome profile);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in stress granules size, number and composition</measure>
    <time_frame>at week 30 compared to baseline</time_frame>
    <description>identification of changes in stress granules response and composition in patients' fibroblasts and lymphoblasts will be carried out by measuring granules size, number and composition by confocal microscopy using automated systems. The aberrant recruitment or sequestration of specific mRNA inside stress granules will be assessed by FISH using specific probes, followed by densitometric analysis as previously described by Gareau et al. (2011).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantification of insoluble species</measure>
    <time_frame>at week 30 compared to baseline</time_frame>
    <description>assessment of overall levels and the relative ratio between soluble and insoluble species of TDP-43, TDP-43 fragments, SQSTM1/p62, UBQLN, OPTN in fibroblasts and lymphoblasts derived from the same patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modifications on extracellular vesicles secretion in blood and CSF</measure>
    <time_frame>at week 30 compared to baseline</time_frame>
    <description>assessment of TDP-43, hyperphosphorylated TDP-43, SQSTM1/p62, UBQLN and OPTN in extracellular vesicles by plasma and CSF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effects on biomarkers of neurodegeneration</measure>
    <time_frame>at week 30 compared to baseline</time_frame>
    <description>creatinine, albumin, CK, and vitamin D in plasma as markers of disease severity; phosphorylated neurofilaments heavy chain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effects on biomarkers of inflammation</measure>
    <time_frame>at week 30 compared to baseline</time_frame>
    <description>assessment of plasma/CSF IL18, its endogenous inhibitor IL-18BP, MCP1 and IL17</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Colchicine 0.01mg/kg/day + Riluzole 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colchicine 0.005 mg/kg/day + Riluzole 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Riluzole 100 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills will be administered at fast, while taking Riluzole 100 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 1 MG Oral Tablet</intervention_name>
    <description>Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (&gt;70 kg or &lt;71 kg) for 30 weeks of duration.</description>
    <arm_group_label>Colchicine 0.01mg/kg/day + Riluzole 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 1 MG Oral Tablet</intervention_name>
    <description>Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (&gt;70 kg or &lt;71 kg) for 30 weeks of duration.</description>
    <arm_group_label>Colchicine 0.005 mg/kg/day + Riluzole 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Corresponding tablets for 30 weeks</description>
    <arm_group_label>Placebo + Riluzole 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with a laboratory supported, clinically &quot;probable&quot; or &quot;definite&quot;
             amyotrophic lateral sclerosis according to the Revised El Escorial criteria (Brooks,
             2000)

          -  Sporadic ALS

          -  ALS phenotypes: classic or bulbar

          -  Female or male patients aged between 18 and 80 years old

          -  Disease duration from symptoms onset no longer than 18 months at the screening visit

          -  Patients treated with a stable dose of Riluzole (100 mg/day) for at least 30 days
             prior to screening

          -  Patients with a weight &gt; 50 kg and a BMI ≥18

          -  Patients with a FVC (Forced Vital Capacity) equal or more than 65 % predicted normal
             value for gender, height, and age at the screening visit Patients able and willing to
             comply with study procedures as per protocol

          -  Patients able to understand, and capable of providing informed consent at screening
             visit prior to any protocol-specific procedures

          -  Use of highly effective contraception

        Exclusion Criteria:

          -  Prior use of Colchicine

          -  Prior allergy/sensitivity to Colchicine

          -  Receiving Colchicine or other anti-inflammatory drugs (such as corticosteroids,
             methotrexate, anti-neoplastic, Interleukin 1-1b antagonist, Tumor necrosis
             factor-alpha inhibitor)

          -  Receiving food or co-medications such as strong-moderate cytochrome P450 3A4
             inhibitors that will result in elevated plasma level of Colchicine

          -  Inflammatory disorders (SLE, Rheumatoid arthritis, connective tissue disorder) or
             chronic infections (HIV, hepatitis B or C infection) or significant history of
             malignancy

          -  Severe renal (eGFR&lt; 30ml/min/1.73m2), or liver failure or liver aminotransferase
             (ALT/AST &gt; 2x Upper limit of normal),

          -  Existing blood dyscrasia (e.g., myelodysplasia)

          -  White blood cells&lt;4,000/mm³, platelets count&lt;100,000/mm³, hematocrit&lt;30%

          -  Severe comorbidities (heart, renal, liver failure), autoimmune diseases or any type of
             interstitial lung disease

          -  Patients who underwent non invasive ventilation, tracheotomy and /or gastrostomy

          -  Women who are pregnant or breastfeeding

          -  Participation in pharmacological studies within the last 30 days before screening

          -  Patients with the following ALS phenotypes: flail arm, flail leg, UMN-p, respiratory,
             PLS, progressive muscular atrophy.

          -  Patients with familial ALS defined as presence of at least one first degree family
             member (parents/son/daughter/brother/sister) affected by ALS.

          -  Patients with known pathogenic mutations (SOD1, TARDBP, FUS, C9ORF72).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Mandrioli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria di Modena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Mandrioli, MD</last_name>
    <phone>059-3961640</phone>
    <email>j.mandrioli@ausl.mo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicola Fini, MD</last_name>
    <phone>0593961640</phone>
    <email>n.fini@ausl.mo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Sla, University of Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabella L Simone, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Sla, Istituto Auxologico Italiano, University of Milano, Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Silani, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irccs Carlo Besta</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ELEONORA DALLA BELLA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irccs St. Raffaele Institute of Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilo Riva, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Sla, Ospedale Civile S. Agostino Estense, A.O.U. Modena</name>
      <address>
        <city>Modena</city>
        <zip>41126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Mandrioli, MD</last_name>
      <phone>+390593961722</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università della Campania Gianluigi Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria R Monsurrò, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Sla, Universita' Di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianni Sorarù, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Als Centre, &quot;C. Mondino&quot; National Neurological Institute, University of Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Ceroni, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>, Neuromuscular Omnicentre Centre, Rome, Catholic University, Rome</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Sabatelli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Sla, Universita' Di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adriano Chiò, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Thomas M, Alegre-Abarrategui J, Wade-Martins R. RNA dysfunction and aggrephagy at the centre of an amyotrophic lateral sclerosis/frontotemporal dementia disease continuum. Brain. 2013 May;136(Pt 5):1345-60. doi: 10.1093/brain/awt030. Epub 2013 Mar 9. Review.</citation>
    <PMID>23474849</PMID>
  </reference>
  <reference>
    <citation>Cadwell K. Crosstalk between autophagy and inflammatory signalling pathways: balancing defence and homeostasis. Nat Rev Immunol. 2016 Nov;16(11):661-675. doi: 10.1038/nri.2016.100. Epub 2016 Oct 3. Review.</citation>
    <PMID>27694913</PMID>
  </reference>
  <reference>
    <citation>Crippa V, D'Agostino VG, Cristofani R, Rusmini P, Cicardi ME, Messi E, Loffredo R, Pancher M, Piccolella M, Galbiati M, Meroni M, Cereda C, Carra S, Provenzani A, Poletti A. Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases. Sci Rep. 2016 Mar 10;6:22827. doi: 10.1038/srep22827.</citation>
    <PMID>26961006</PMID>
  </reference>
  <reference>
    <citation>Crippa V, Cicardi ME, Ramesh N, Seguin SJ, Ganassi M, Bigi I, Diacci C, Zelotti E, Baratashvili M, Gregory JM, Dobson CM, Cereda C, Pandey UB, Poletti A, Carra S. The chaperone HSPB8 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity. Hum Mol Genet. 2016 Sep 15;25(18):3908-3924. doi: 10.1093/hmg/ddw232. Epub 2016 Jul 27.</citation>
    <PMID>27466192</PMID>
  </reference>
  <reference>
    <citation>Cristofani R, Crippa V, Vezzoli G, Rusmini P, Galbiati M, Cicardi ME, Meroni M, Ferrari V, Tedesco B, Piccolella M, Messi E, Carra S, Poletti A. The small heat shock protein B8 (HSPB8) efficiently removes aggregating species of dipeptides produced in C9ORF72-related neurodegenerative diseases. Cell Stress Chaperones. 2018 Jan;23(1):1-12. doi: 10.1007/s12192-017-0806-9. Epub 2017 Jun 12.</citation>
    <PMID>28608264</PMID>
  </reference>
  <reference>
    <citation>Cristofani R, Crippa V, Rusmini P, Cicardi ME, Meroni M, Licata NV, Sala G, Giorgetti E, Grunseich C, Galbiati M, Piccolella M, Messi E, Ferrarese C, Carra S, Poletti A. Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases. Autophagy. 2017 Aug 3;13(8):1280-1303. doi: 10.1080/15548627.2017.1308985.</citation>
    <PMID>28402699</PMID>
  </reference>
  <reference>
    <citation>Carra S, Seguin SJ, Landry J. HspB8 and Bag3: a new chaperone complex targeting misfolded proteins to macroautophagy. Autophagy. 2008 Feb;4(2):237-9. Epub 2007 Dec 11. Review.</citation>
    <PMID>18094623</PMID>
  </reference>
  <reference>
    <citation>Crippa V, Sau D, Rusmini P, Boncoraglio A, Onesto E, Bolzoni E, Galbiati M, Fontana E, Marino M, Carra S, Bendotti C, De Biasi S, Poletti A. The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). Hum Mol Genet. 2010 Sep 1;19(17):3440-56. doi: 10.1093/hmg/ddq257. Epub 2010 Jun 22.</citation>
    <PMID>20570967</PMID>
  </reference>
  <reference>
    <citation>Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009 Jun;38(6):411-9. doi: 10.1016/j.semarthrit.2008.08.006. Epub 2008 Oct 29. Review.</citation>
    <PMID>18973929</PMID>
  </reference>
  <reference>
    <citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016 Nov 10;539(7628):197-206. doi: 10.1038/nature20413. Review.</citation>
    <PMID>27830784</PMID>
  </reference>
  <reference>
    <citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012 Mar 14;(3):CD001447. doi: 10.1002/14651858.CD001447.pub3. Review.</citation>
    <PMID>22419278</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria di Modena</investigator_affiliation>
    <investigator_full_name>Jessica Mandrioli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>stress granules</keyword>
  <keyword>HSPB8</keyword>
  <keyword>protein quality control</keyword>
  <keyword>colchicine</keyword>
  <keyword>ALSFRS-r</keyword>
  <keyword>survival</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>de-identified individual participant data will be made available after study completion upon specific request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will become available at study completion (after final data analysis)</ipd_time_frame>
    <ipd_access_criteria>specific personal request by the subject</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

